RPSE Res.Phm.Reg S

    RNS Number : 2858U
  Research Pharmaceutical SRV, Inc
  13 May 2008
   

    13 May 2008
    ReSearch Pharmaceutical Services, Inc.

    Board changes

    ReSearch Pharmaceutical Services, Inc. ("RPS" or the "Company") is pleased to announce the appointment of four new Non-executive
Directors to the Board with immediate effect.  These appointments are an important development for the company and bring significant
experience to the Board. Details for the four new Non-executive Directors are set out below.

    Jack Hugh Dean, Ph.D., aged 66, has significant experience in pharmaceuticals research and development with 18 years experience in drug
development with Sanofi-Aventis and over 35 years of research management experience including the National Institutes of Health.  Dr. Dean
retired in January 2006 as the President of U.S. Science and Medical Affairs at Sanofi-Aventis and the Global Director of Preclinical
Development for Sanofi-Aventis, SA.  Dr. Dean is currently a director of Drug Development Advisors, LLC, his consulting organization, and
was previously a director of Sanofi-Synthelabo CRU, a subsidiary of Sanofi-Synthelabo, Inc.

    Warren Wayne Myers, aged 46, has over 20 years of management experience in the pharmaceuticals market. Mr. Myers presently serves as a
consultant to the bio-pharmaceutical industry, and most recently was the Executive Director, Strategic Sourcing and Procurement at Amgen
Inc. serving Amgen's Research and Development organization.

    Peter Michael Yu, aged 46, is a founder and the Managing Partner of Cartesian Capital Group, LLC ("Cartesian"), a global private equity
firm with more than $1 billion under management. Prior to founding Cartesian, Mr. Yu founded and served as President and CEO of AIG Capital
Partners, a global private equity firm with $4.5 billion under management. In addition, Mr. Yu is currently a director of Cartesian Asset
Management, LLC., and was formerly a director of Brasil Media Exterior and Gol Linhas Aereas Inteligentes S.A.

    Thomas Robert Armstrong, aged 63, is a founder and Partner at Cartesian. Prior to founding Cartesian, Mr. Armstrong served as Senior
Advisor to AIG Capital Partners from 1999 until 2005. Prior to that Mr. Armstrong was COO and a founding partner and director of Advent
International Corporation. In addition, Mr. Armstrong is currently a partner of Technology, Research and Education Associates and a director
of SCM Private Equity Ltd and SCM Private Equity II Ltd and was previously a partner of Echelon Ventures II Management and a co-founder and
former director of Thrasos Therapeutics, Inc. and former director of Lexent Technologies, Inc.

    Due to Cartesian's interest in the Company's shares, Mr. Armstrong and Mr. Yu are not considered to be independent according to the
rules applicable to AIM companies.

    Each of the above individuals has confirmed to the Company that there is no further information to be disclosed in relation to the above
appointment pursuant to Schedule 2 paragraph (g) and Rule 17 of the AIM Rules for Companies.

    Daniel Perlman, Chairman of RPS, commented:
    "The expansion of our Board adds new industry and business expertise to our Company.  We are looking forward to benefiting from their
insights, experience and opinions as we continue our growth and global expansion."

    Enquiries:

    ReSearch Pharmaceutical Services, Inc.:                                 +1-215-540-0700
    Daniel M. Perlman, Chairman & Chief Executive Officer
    Steven Bell, Chief Financial Officer

    Nominated Adviser and UK Broker:                                     +44-20-7012-2000
    Arbuthnot Securities Limited
    James Steel/Richard Tulloch
This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
BOASFLSADSASEII

Res.Phm.Reg S (LSE:RPSE)
Historical Stock Chart
From May 2024 to May 2024

Res.Phm.Reg S (LSE:RPSE)
Historical Stock Chart
From May 2023 to May 2024